Unraveling the unforeseen: anuric acute kidney injury induced by alectinib

Prior research has shown that alectinib serves as a highly effective second-generation inhibitor of anaplastic lymphoma kinase (ALK) for treating advanced malignancies. This pharmacological agent has transformed the therapeutic landscape for patients diagnosed with ALK-positive non-small cell lung cancer (NSCLC) by offering superior progression-free survival. While the safety profile of this tyrosine kinase inhibitor is generally considered favorable, clinicians must remain aware of potential systemic toxicities. Renal complications, specifically acute kidney injury (AKI), are documented as rare but clinically significant adverse events that can jeopardize patient health. The underlying mechanisms of drug-induced nephrotoxicity often involve complex interactions between the therapeutic compound and renal tubular cells. Identifying specific risk factors and presentation patterns is vital for maintaining the long-term viability of oncological treatment plans. This absence of evidence motivated the detailed examination of alectinib-induced anuric renal failure in a clinical setting.

This case study evaluates the clinical presentation and management of severe anuric acute kidney injury (AKI) triggered by alectinib administration. The investigation focuses on a seventy-one-year-old female patient who developed sudden renal failure after two months of targeted therapy. Researchers sought to document the rapid progression from baseline renal function to a state requiring emergent medical intervention. The study aims to highlight the intersection of pre-existing comorbidities, such as diabetes, with the risk of drug-induced organ damage. By detailing the successful recovery process, the authors provide evidence for the reversibility of this specific toxic effect. The report also explores the feasibility of transitioning to brigatinib as a secondary therapeutic option for ALK-positive non-small cell lung cancer. This documentation provides essential guidance for oncologists encountering unexpected renal toxicity during standard dosing regimens.

The clinical team conducted a longitudinal assessment of a patient receiving 600 mg of alectinib twice daily for the management of pulmonary adenocarcinoma. Diagnostic monitoring included the evaluation of respiratory symptoms and the quantification of urinary output to identify the onset of anuria. Laboratory technicians performed serial serum creatinine measurements to track the decline in glomerular filtration capacity over the treatment period. Upon the discovery of severe renal impairment, the medical staff immediately suspended the administration of the anaplastic lymphoma kinase inhibitor. The therapeutic strategy incorporated a single session of hemodialysis to manage acute metabolic disturbances and facilitate the removal of excess fluid. Following the restoration of renal function, the patient transitioned to a regimen of brigatinib to maintain control over the underlying malignancy. Researchers monitored the patient for four months post-transition to ensure the stability of renal parameters and the absence of recurrent toxicity.

Initial diagnostic findings confirmed a dramatic increase in serum creatinine levels, which rose from a baseline of 1.0 mg/dL to 3.64 mg/dL. The patient presented with clinical signs of anuria and shortness of breath, necessitating immediate hospitalization and intensive care. Following the cessation of the second-generation inhibitor, the individual exhibited a rapid and significant recovery of renal filtration capacity. A single session of extracorporeal hemodialysis proved sufficient to stabilize the patient's metabolic state and resolve the acute symptoms. The medical team successfully discharged the patient without the requirement for long-term renal replacement therapy or further dialytic support. During the subsequent four-month follow-up period, the patient maintained stable renal function while receiving brigatinib as an alternative therapy. These results demonstrate that prompt recognition of alectinib-induced nephrotoxicity can lead to a full restoration of organ function.

The occurrence of anuric acute kidney injury (AKI) underscores the necessity for rigorous renal monitoring during alectinib therapy for non-small cell lung cancer. This case demonstrates that even well-tolerated second-generation inhibitors can induce severe, life-threatening organ dysfunction in susceptible individuals. Patients with underlying conditions like diabetes may face an elevated risk of experiencing drug-induced renal insults during oncological treatment. The rapid recovery observed after drug withdrawal suggests that the nephrotoxic effects of this specific kinase inhibitor are potentially reversible. Brigatinib appears to be a viable and safe alternative for patients who exhibit intolerance to the primary ALK-targeted agent. Future clinical guidelines should emphasize the importance of early intervention and the potential need for temporary renal support in cases of severe toxicity. Maintaining a high index of suspicion for renal complications is essential for optimizing the long-term outcomes of patients undergoing targeted cancer therapy.